Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations

Akira Fujii, Norio Yasui-Furukori, Taku Nakagami, Takenori Niioka, Manabu Saito, Yasushi Sato, Sunao Kaneko, Akira Fujii, Norio Yasui-Furukori, Taku Nakagami, Takenori Niioka, Manabu Saito, Yasushi Sato, Sunao Kaneko

Abstract

Objective: A study was conducted to establish the bioequivalence between different sustained-release formulations of valproic acid (Depakene R and Selenica R), which were developed in Japan.

Materials and methods: The clinical investigation was designed in a randomized, crossover fashion with a single dose given to 12 healthy subjects. The subjects were administered a single 600 mg dose of valproic acid in one of two formulations. Serial venous blood samples were obtained over 72 hours after each administration to measure valproic acid in serum by enzyme immunoassay (EIA). In addition, a dissolution test was performed. Each sample was analyzed by an high-performance liquid chromatography to determine the dissolution rate of valproic acid.

Results: No difference in maximum concentration or area under the curve was found between the two formulations. The time to maximum concentration of the new formation was significantly delayed compared with the conventional formulation (10.8 +/- 1.7 versus 17.6 +/- 1.8 hours, p < 0.001). Apparent clearance or elimination half-life did not differ between the two formulations. An in vitro dissolution study showed that Depakene R was significantly more dissoluble than Selenica R.

Conclusion: Based on the results, the present study demonstrated a significant difference between the two sustained-release formulations in the absorption profile, and also demonstrated that the bioavailability of valproic acid in the two formulations was similar but absorption speed (lag time) was very different.

Keywords: Depakene R; Selenica R; bioequivalence; sustained-release; valproic acid.

Figures

Figure 1
Figure 1
Dissolution profiles of Depakene R and Selenica R. Error bars indicate standard errors. Open and solid circles are the data for Depakene R and Selenica R, respectively. Notes: *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 2
Figure 2
Tablet characteristics for the slow-release preparations of Depakene R and Selenica R.
Figure 3
Figure 3
Serum concentration-time curves of valproic acid after single oral doses of Depakene R and Selenica R. Error bars indicate standard errors. Open and solid circles are the data for Depakene R and Selenica R, respectively. Notes: *p < 0.05, **p < 0.01, ***p < 0.001.

References

    1. Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications. Clin Pharmacokinet. 1992;22:11–21.
    1. Bowden CL, Singh V. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand Suppl. 2005;426:13–20.
    1. Buck D, Jacoby A, Baker GA, et al. Factors influencing compliance with antiepileptic drug regimes. Seizure. 1997;6:87–93.
    1. Cramer J, Vachon L, Desforges C, et al. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia. 1995;36:1111–7.
    1. Doughty J, Baker GA, Jacoby A, et al. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav. 2003;4:710–6.
    1. Eadie MJ. Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance. Clin Pharmacokinet. 1991;21:27–41.
    1. Fujisaki Y, Tsukune T, Funyu M, et al. Development of sustained-release tablets containing sodium valproate: in vitro and in vivo correlation. Drug Dev Ind Pharm. 2006;32:207–17.
    1. Genton P. Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate. Acta Neurol Scand Suppl. 2005;182:26–32.
    1. Gugler G, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet. 1980;5:67–83.
    1. Nasrallah HA, Ketter TA, Kalali AH. Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature. J Affect Disord. 2006;95:69–78.
    1. Pellock JM, Smmith MC, Cloyd JC, et al. Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy. Epilepsy Behav. 2004;5:301–7.
    1. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16:695–714.
    1. Pugh CB, Garnett WR. Current issues in the treatment of epilepsy. Clin Pharm. 1991;10:335–58.
    1. Yasui-Furukori N, Saito M, Nakagami T, et al. Different serum concentrations of steady-state valproic acid in two sustained-release formulations. Psychiatry Clin Neurosci. 2007;61:308–12.
    1. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid-1988. Clin Pharmacokinet. 1988;15:367–89.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner